P
Pacira Biosciences
Non-opioid pain management innovations
About Pacira Biosciences
Pacira Biosciences, Inc. is a pharmaceutical company that provides non-opioid pain management and regenerative health solutions.
The company's flagship product, EXPAREL, is a local analgesic that is used for postsurgical pain management. EXPAREL is a bupivacaine liposome injectable suspension that is administered at the time of surgery. The company also markets iovera, a handheld device that uses cryoanalgesia to temporarily block pain signals from peripheral nerves.
Pacira Biosciences serves hospitals, ambulatory surgery centers, and physicians in the United States. The company's business model is based on the sale of its products to these customers. Pacira Biosciences generates revenue through the sale of EXPAREL and iovera.
The company is focused on expanding the use of its products in new indications and geographies. Pacira Biosciences is also developing new products to address unmet needs in pain management and regenerative health.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 1989
- Headquarters
- Brisbane, United States
- Listing
- IPO 2011
- Employees
- 884
- Open positions
- 20
- Dealroom signal
- 74.5/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology
- Client focus
- b2b
- Investment activity
- 11 companies, latest Feb 2025
- Capital deployed
- $90M
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO DEBTDebt | Jul 2025 | $300M | — | Undisclosed | ↗ |
| POST IPO CONVERTIBLEOther financing | May 2024 | $250M | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $768M | +5.7% | $185M | 24.1% |
| 2025 | $726M | +3.6% | $138M | 18.9% |
| 2024 | $701M | +3.9% | $193M | 27.5% |
| 2023 | $675M | +1.2% | $171M | 25.4% |
| 2022 | $667M | +23.1% | $121M | 18.2% |
| 2021 | $542M | +28.7% | $145M | 26.7% |
| 2020 | $421M | — | $67M | 15.9% |
Growth signals
Latest recorded traffic for Pacira Biosciences is 16K monthly website visits, up 255.6% over the last three months. Pacira Biosciences's team grew 6.6% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
GQ Bio TherapeuticsHamburg, GermanyDevelops novel therapies for osteoarthritis, a degenerative joint disease with high unmet medical need
$24Mvaluation
GenascencePalo Alto, United StatesDeveloping revolutionized life changing gene therapies for prevalent musculoskeletal and joint diseases
$42Mvaluation
CarthroniXLos Angeles, United StatesBiopharmaceutical innovations for degenerative diseases, focusing on cartilage repair, inflammation suppression, and skin regeneration
→
Spine BioPharmaNew York City, United StatesSpine Biopharma has developed a non-surgical solution for those struggling with debilitating back pain
$65Mvaluation
CODA BiotherapeuticsSouth San Francisco, United StatesCODA Biotherapeutics is a preclinical-stage biopharmaceutical company
$112Mvaluation
Flexion TherapeuticsWoburn, United StatesBiopharmaceutical company focused on advancing innovative, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis
$428Mvaluation
Avalon.aiNew York City, United States
$6Mvaluation
ioveraFremont, United StatesMyoScience develops and commercializes technology-driven dermatological products
$140Mvaluation
TELA BioMalvern, United StatesLife science company offering surgical reconstruction
$61Mvaluation
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
OrbiMed
HBM Healthcare Investments
MPM BioImpact
Sanderling Ventures
Series B and later1 investor entered at this stage
Oxford Finance
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Pacira Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Pacira Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.